Current State of ALS Research


  • Little concentrated effort  by Pharma and Biotech companies  to produce a drug
  • Little is known about the disease.
    • No biomarkers.
    • Hard to create a cure for something that can’t be identified
  • No new ALS drug in over 22 years since Relizolein 1995
    • Only ALS drug available (upside is 10% reduction in decay rate)
    • Radicava, in 2017 was a repurposed stroke drug;  Questionable success
piggy-bank-1019758_640

Rare Disease = Low Revenue Potential


  • $$$$ US Cancer population = 2 million
  • $ US ALS Population = 20,000 to 25,000